From our pages to your practice

We have some interesting and insightful articles lined up for you this month, beginning with a Commentary by Samuel and Stone on treating HER2-positive breast cancer and asking whether the era of trastuzumab therapy is over. The Commentary and accompanying Community Translations report explore the use of pertuzumab and trastuzumab together, especially in the neoadjuvant setting. The Cleopatra trial has already shown that combining pertuzumab with trastuzumab plus docetaxel as a first-line treatment for HER2-positive metastatic breast cancer significantly prolonged progression-free survival with no increase in cardiac toxic effects, compared with placebo plus trastuzumab plus docetaxel, so perhaps using pertuzumab and trastuzumab upfront might be equally successful.

Click on the PDF icon at the top of this introduction to read the full article.